Gilead Sciences, Inc. vs NRG Energy Inc — how do they compare? Gilead Sciences, Inc. trades at $132.77 (market cap $163.51B), while NRG Energy Inc trades at $135.07 (market cap $29.10B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× NRG Energy Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NRG | |
|---|---|---|
Market Cap | $163.51B | $29.10B |
Sector | Health | Utilities |
52-Week High | $155.80 | $184.03 |
52-Week Low | $108.22 | $120.65 |
Enterprise Value | $178.05B | $52.92B |
Dividend Yield | 2.49% | 1.38% |
Trailing returns across standard periods
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →